Future studies using amyloid- and tau-PET will investigate these potential associations between molecular pathology and navigational behaviour in the early stages of Alzheimer’s disease further, and the relative contribution of amyloid-β and tau to the observed behavioural deficits. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.